201 related articles for article (PubMed ID: 38454010)
1. Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities.
Bettadapura S; Dowling K; Jablon K; Al-Humadi AW; le Roux CW
Int J Obes (Lond); 2024 Mar; ():. PubMed ID: 38454010
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials.
Aldawsari M; Almadani FA; Almuhammadi N; Algabsani S; Alamro Y; Aldhwayan M
Diabetes Metab Syndr Obes; 2023; 16():575-595. PubMed ID: 36890965
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.
Hyde KM; Blonde GD; le Roux CW; Spector AC
Physiol Behav; 2017 Aug; 177():4-12. PubMed ID: 28366815
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
Kadouh H; Chedid V; Halawi H; Burton DD; Clark MM; Khemani D; Vella A; Acosta A; Camilleri M
J Clin Endocrinol Metab; 2020 May; 105(5):1552-63. PubMed ID: 31665455
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine regulation of appetitive ingestive behavior.
Keen-Rhinehart E; Ondek K; Schneider JE
Front Neurosci; 2013 Nov; 7():213. PubMed ID: 24298235
[TBL] [Abstract][Full Text] [Related]
6. Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.
Marty VN; Farokhnia M; Munier JJ; Mulpuri Y; Leggio L; Spigelman I
Front Neurosci; 2020; 14():599646. PubMed ID: 33424537
[TBL] [Abstract][Full Text] [Related]
7. Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight.
López-Ferreras L; Richard JE; Noble EE; Eerola K; Anderberg RH; Olandersson K; Taing L; Kanoski SE; Hayes MR; Skibicka KP
Mol Psychiatry; 2018 May; 23(5):1157-1168. PubMed ID: 28894301
[TBL] [Abstract][Full Text] [Related]
8. Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression.
Wagner S; Brierley DI; Leeson-Payne A; Jiang W; Chianese R; Lam BYH; Dowsett GKC; Cristiano C; Lyons D; Reimann F; Gribble FM; Martinez de Morentin PB; Yeo GSH; Trapp S; Heisler LK
Mol Metab; 2023 Feb; 68():101665. PubMed ID: 36592795
[TBL] [Abstract][Full Text] [Related]
9. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms for AgRP neuron-mediated regulation of appetitive behaviors in rodents.
Thomas MA; Xue B
Physiol Behav; 2018 Jun; 190():34-42. PubMed ID: 29031550
[TBL] [Abstract][Full Text] [Related]
11. Effects of a glucagon-like peptide-1 analog on appetitive and consummatory behavior for rewarding and aversive gustatory stimuli in rats.
Douton JE; Norgren R; Grigson PS
Physiol Behav; 2021 Feb; 229():113279. PubMed ID: 33285178
[TBL] [Abstract][Full Text] [Related]
12. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 physiology informs the pharmacotherapy of obesity.
Drucker DJ
Mol Metab; 2022 Mar; 57():101351. PubMed ID: 34626851
[TBL] [Abstract][Full Text] [Related]
16. The Discovery and Development of Liraglutide and Semaglutide.
Knudsen LB; Lau J
Front Endocrinol (Lausanne); 2019; 10():155. PubMed ID: 31031702
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats.
Oertel M; Ziegler CG; Kohlhaas M; Nickel A; Kloock S; Maack C; Sequeira V; Fassnacht M; Dischinger U
Endocr Connect; 2024 Mar; 13(3):. PubMed ID: 38300808
[TBL] [Abstract][Full Text] [Related]
18. Severe sleep restriction suppresses appetite independent of effects on appetite regulating hormones in healthy young men without obesity.
Radcliffe PN; Whitney CC; Fagnant HS; Wilson MA; Finlayson G; Smith TJ; Karl JP
Physiol Behav; 2021 Aug; 237():113438. PubMed ID: 33940082
[TBL] [Abstract][Full Text] [Related]
19. GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy.
Lafferty RA; Flatt PR; Irwin N
Expert Opin Pharmacother; 2023 Apr; 24(5):587-597. PubMed ID: 36927378
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
